Bousser MG. Stroke in women: the 1997 Paul Dudley White International Lecture. Circulation.1999;99:463-7.
Bonita R. Epidemiology of stroke. Lancet.1992;339:342-344.
Murphy SL. Deaths: final data for 1998. Natl Vital Stat Rep.2000;48:1-105.
Not Available. Design of the Women's Health Initiative clinical trial and observational
study: the Women's Health Initiative Study Group Control Clin Trials.1998;19:61-109.
Rossouw JE, Anderson GL, Prentice RL.
et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal
women: principal results from the Women's Health Initiative randomized controlled
Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA.2000;284:72-78.
Hulley S, Grady D, Bush T.
et al. for the Heart and Estrogen/progestin Replacement Study (HERS) Research
Group. Randomized trial of estrogen plus progestin for secondary prevention
of coronary heart disease in postmenopausal women. JAMA.1998;280:605-613.
Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med.2001;345:1243-1249.
Simon JA, Hsia J, Cauley JA.
et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin
Replacement Study (HERS). Circulation.2001;103:638-642.
Hart CL, Hole DJ, Smith GD. Risk factors and 20-year stroke mortality in men and women in the Renfrew/Paisley
study in Scotland. Stroke.1999;30:1999-2007.
Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke: the Framingham Study. JAMA.1988;259:1025-1029.
Whisnant JP. Modeling of risk factors for ischemic stroke: the Willis Lecture. Stroke.1997;28:1840-1844.
Gorelick PB, Sacco RL, Smith DB.
et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary
consensus statement from the National Stroke Association. JAMA.1999;281:1112-1120.
Inzitari D, Eliasziw M, Gates P.
et al. for the North American Symptomatic Carotid Endarterectomy Trial Collaborators. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery
stenosis. N Engl J Med.2000;342:1693-700.
Barnett HJ, Gunton RW, Eliasziw M.
et al. Causes and severity of ischemic stroke in patients with internal carotid
artery stenosis. JAMA.2000;283:1429-1436.
Rohde LE, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently
healthy men. Am J Cardiol.1999;84:1018-1022.
Makris TK, Stavroulakis GA, Krespi PG.
et al. Fibrinolytic/hemostatic variables in arterial hypertension: response
to treatment with irbesartan or atenolol. Am J Hypertens.2000;13:783-788.
Hak AE, Stehouwer CD, Bots ML.
et al. Associations of C-reactive protein with measures of obesity, insulin
resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol.1999;19:1986-1991.
Mustonen P, Lepantalo M, Lassila R. Physical exertion induces thrombin formation and fibrin degradation
in patients with peripheral atherosclerosis. Arterioscler Thromb Vasc Biol.1998;18:244-249.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently
healthy men [published correction appears in N Engl J Med. N Engl J Med.1997;337:356]. 1997;336:973-979.
Devaraj S, Jialal I. Low-density lipoprotein postsecretory modification, monocyte function,
and circulating adhesion molecules in type 2 diabetic patients with and without
macrovascular complications: the effect of alpha-tocopherol supplementation. Circulation.2000;102:191-196.
Lip GY, Lip PL, Zarifis J.
et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis
and platelet activation in atrial fibrillation: effects of introducing ultra-low-dose
warfarin and aspirin. Circulation.1996;94:425-431.
De Caterina R, Cybulsky MI, Clinton SK, Gimbrone Jr MA, Libby P. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression
of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb.1994;14:1829-1836.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes
of cerebral infarction. Lancet.1991;337:1521-1526.
Adams Jr HP, Bendixen BH, Kappelle LJ.
et al. for TOAST Trial of Org 10172 in Acute Stroke Treatment. Classification of subtype of acute ischemic stroke: definitions for
use in a multicenter clinical trial. Stroke.1993;24:35-41.
Goldstein LB, Jones MR, Matchar DB.
et al. Improving the reliability of stroke subgroup classification using the
Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. Stroke.2001;32:1091-1098.
Madden KP, Karanjia PN, Adams Jr HP, Clarke WR. Accuracy of initial stroke subtype diagnosis in the TOAST study: Trial
of ORG 10172 in Acute Stroke Treatment. Neurology.1995;45:1975-1979.
Lindley RI, Warlow CP, Wardlaw JM, Dennis MS, Slattery J, Sandercock PA. Interobserver reliability of a clinical classification of acute cerebral
Jennett B, Snoek J, Bond MR, Brooks N. Disability after severe head injury: observations on the use of the
Glasgow Outcome Scale. J Neurol Neurosurg Psychiatry.1981;44:285-293.
Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet.1975;1:480-484.
Ainsworth BE, Haskell WL, Leon A. Compendium of physical activities: classification of energy costs of
human activities. Med Sci Sports Exerc.1993;25:71-80.
D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication: The
Framingham Study. Stroke.1994;25:40-43.
Steiner P, Freidl J, Bremner W, Stein E. Standardization of micromethods for plasma cholesterol, triglyceride
and HDL-cholesterol with the lipid clinics' methodology. J Clin Chem.1981;19:850.
Warnick GR, Albers JJ. A comprehensive evaluation of the heparin manganese precipitation procedure
for estimating high-density lipoprotein cholesterol. J Lipid Res.1978;19:65-76.
Friedewald WT, Levy RI, Frederickson DS. Estimation of concentration of low-density lipoprotein cholesterol
in plasma, without the use of the preparative ultracentrifuge. Clin Chem.1972;18:499-502.
Vu Dac N, Mezdour H, Parra HJ, Luc G, Luyeye I, Fruchart JC. A selective bi-site immunoenzymatic procedure for human Lp(a) lipoprotein
quantification using monoclonal antibodies against apo[a] and apoB. J Lipid Res.1989;30:1437-1443.
Russell WG. Measurement and clinical significance of high-density lipoprotein cholesterol
subclasses. In: Rifai-Warnick, ed. Laboratory Measurement of
Lipids, Lipoproteins, and Apolipoproteins; 1994:207-222.
Paganini-Hill A. Estrogen replacement therapy and stroke. Prog Cardiovasc Dis.1995;38:223-242.
Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ.1988;297:519-522.
Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy:
an updated analysis. Br J Obstet Gynaecol.1990;97:1080-1086.
Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreased risk of stroke among postmenopausal hormone users: results
from a national cohort. Arch Intern Med.1993;153:73-79.
Falkeborn M, Persson I, Terent A, Adami HO, Lithell H, Bergstrom R. Hormone replacement therapy and the risk of stroke: follow-up of a
population-based cohort in Sweden. Arch Intern Med.1993;153:1201-1209.
Petitti DB, Sidney S, Quesenberry Jr CP, Bernstein A. Ischemic stroke and use of estrogen and estrogen/progestogen as hormone
replacement therapy. Stroke.1998;29:23-28.
Pedersen AT, Lidegaard O, Kreiner S, Ottesen B. Hormone replacement therapy and risk of non-fatal stroke. Lancet.1997;350:1277-1283.
Boysen G, Nyboe J, Appleyard M.
et al. Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke.1988;19:1345-1353.
Lemaitre RN, Heckbert SR, Psaty BM, Smith NL, Kaplan RC, Longstreth Jr WT. Hormone replacement therapy and associated risk of stroke in postmenopausal
women. Arch Intern Med.2002;162:1954-1960.
Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular
morbidity in women over 50: the Framingham Study. N Engl J Med.1985;313:1038-1043.
Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA.2002;288:872-281.
Hurn PD, Macrae IM. Estrogen as a neuroprotectant in stroke. J Cereb Blood Flow Metab.2000;20:631-652.
Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial
infarction among apparently healthy men. Circulation.2000;101:1767-1772.
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction
of cardiovascular disease in women. N Engl J Med.2000;342:836-843.